Free tool
FAERS Monitor: Purixan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205919 or its brand name (Purixan, Mercaptopurine). Reports on generic versions are filed under their own applications.
Reports
18,153
Serious
15,651
86% of reports
Hospitalization
8,092
Death reported
1,997
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia1,952
- off label use1,399
- pyrexia1,229
- drug ineffective1,122
- nausea825
- vomiting796
- abdominal pain724
- diarrhoea721
- neutropenia627
- headache614
- fatigue567
- pneumonia541
- crohn^s disease534
- sepsis513
- anaemia483
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 192 |
| 2005 | 151 |
| 2006 | 163 |
| 2007 | 223 |
| 2008 | 272 |
| 2009 | 478 |
| 2010 | 554 |
| 2011 | 643 |
| 2012 | 830 |
| 2013 | 465 |
| 2014 | 765 |
| 2015 | 817 |
| 2016 | 928 |
| 2017 | 1,156 |
| 2018 | 1,319 |
| 2019 | 1,277 |
| 2020 | 1,187 |
| 2021 | 1,379 |
| 2022 | 1,435 |
| 2023 | 1,287 |
| 2024 | 1,190 |
| 2025 | 859 |
| 2026 | 583 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,006 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 1,952 | 35.1 | 33.6 | 62,927 |
| neutropeniaSignal | 627 | 5.4 | 5.0 | 2,225 |
| sepsisSignal | 513 | 5.3 | 4.9 | 1,811 |
| pyrexiaSignal | 1,229 | 4.1 | 3.9 | 2,946 |
| abdominal painSignal | 724 | 3.6 | 3.4 | 1,377 |
| anaemiaSignal | 483 | 2.9 | 2.7 | 620 |
| vomiting | 796 | 2.0 | 1.8 | 383 |
| pneumonia | 541 | 1.9 | 1.8 | 248 |
| off label use | 1,399 | 1.9 | 1.8 | 571 |
| diarrhoea | 721 | 1.3 | 1.2 | 49 |
| nausea | 825 | 1.2 | 1.1 | 30 |
| headache | 614 | 1.1 | 1.0 | 10 |
| drug ineffective | 1,122 | 1.0 | 0.9 | 0 |
| fatigue | 567 | 0.8 | 0.8 | 17 |
| crohn^s disease | 534 | 0.0 | 0.0 | 617,665 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.